Devyser Diagnostics announced that the company has signed an exclusive collaboration and distribution agreement with Thermo Fisher. The agreement gives Thermo Fisher exclusive rights to commercialize, under combined brands, Devyser’s post-transplant portfolio of NGS products in North America and Europe. The collaboration and distribution agreement signed today gives Thermo Fisher exclusive rights to market and sell, under combined brands, Devyser’s post-transplant portfolio in North America and Europe. Devyser retains the rights to commercialize its post-transplant products in US via its own service laboratory, as a service to US laboratories. Devyser will continue to manufacture all products under the agreement.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TMO:
- Citi expects weakness for Danaher, Thermo Fisher after Sartorius results
- PhenomeX appoints Silvester to board of directors
- Thermo Fisher price target lowered to $625 from $660 at Barclays
- ‘The End of the Bear Market May Be in Sight,’ Says Morgan Stanley. Here Are 3 Stocks the Banking Giant Likes for Long-Term Growth
- Thermo Fisher opens cell therapy facility at UCSF
